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After the publication of this work \[[@CR1]\] errors were noticed in Figs. [1](#Fig1){ref-type="fig"}a, [6](#Fig2){ref-type="fig"}a, and [8](#Fig3){ref-type="fig"}a---in which the β-actin bands were mistakenly presented. The corrected Figs. [1](#Fig1){ref-type="fig"}, [6](#Fig2){ref-type="fig"}, and [8](#Fig3){ref-type="fig"} are presented below. The correction does not affect our conclusions. Nevertheless, we apologize for this error.Fig. 1Expression levels of Bcl-2 and Bcl-xL proteins in MDA-MB-231, MDA MD-453, BT-474, and ZR-75-1 cells. **a** Western blot analysis of Bcl-2 and Bcl-xL expression. **b** Quantification of Bcl-2 and Bcl-xL expression by densitometric analysis. The relative expression of Bcl-2 and BclxL in MDA-MB-453 cells was compared with the expression in MDAMB-231, BT-474, and ZR-75-1 cells. Results are from two representative, independent experimentsFig. 6Effects of treatment with antisense *Bcl-2* and mitomycin C, doxorubicin, paclitaxel, or docetaxel on BT-474 cells. **a** Expression levels of Bcl-2 and Bcl-xL protein in BT-474 cells transplanted into athymic mice after treatment with antisense (AS) *Bcl-2* oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. **b** Enhancement of the antitumor effects of anticancer drugs by AS *Bcl-2* ODNs in BT-474 tumor xenografts. Each point represents the mean tumor volume of the eight mice in each group. Error bars indicate SD. \*, *P* \< 0.05, analysis of variance with Fisher\'s least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxoru- bicin;TXL, paclitaxel; TXT, docetaxelFig. 8Effects of treatment with antisense *Bcl-xL* and mitomycin C, doxorubicin, paclitaxel, or docetaxel on MDA-MB-231 cells. **a** Expression levels of Bcl-xL and Bcl-2 protein in MDA-MB-231 cells transplanted into athymic mice after treatment with antisense (AS) *Bcl-xL* oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. **b** Enhancement of the antitumor effects of anticancer drugs by AS *Bcl-xL* ODNs in MDA-MB-231 tumor xenografts. Each point represents the mean tumor volume of the four mice in each group. Error bars indicate SD. \*, *P*\< 0.05, analysis of variance with Fisher\'s least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxorubicin; TXL, paclitaxel; TXT, docetaxel
